{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:40:31Z","timestamp":1761745231435},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>After transurethral resection of a bladder tumor, patients frequently have a recurrence of the disease, thereby requiring adjuvant therapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>The study aimed to determine the prognostic value of expression levels of p53, Ki-67, and survivin, and to develop a new prognostic model for patients with non-muscle-invasive bladder cancer (NMIBC) after transurethral resection of a bladder tumor.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The study group consisted of 101 patients with primary NMIBC. Univariate followed by multivariate Cox proportional hazard regression analysis was performed to obtain a model including the smallest possible number of descriptive variables with the highest statistical significance and impact on risk.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The RECINT model (RECurrence In Not Treated) including factors independently associated with cancer recurrence (tumor size [HR 1.148; <jats:italic>p<\/jats:italic>\u2009=\u20090.034], intensity of the color reaction for p53 [HR 1.716; <jats:italic>p<\/jats:italic>\u2009=\u20090.008], Ki-67 [HR 3.001; <jats:italic>p<\/jats:italic>\u2009=\u20090.022], and survivin [HR 1.461; <jats:italic>p<\/jats:italic>\u2009=\u20090.021]) adequately stratified recurrence free-survival (<jats:italic>R<\/jats:italic><jats:sup>2<\/jats:sup>\u2009=\u20090.341, p\u2009&lt;\u20090.001) in patients with primary NMIBC. Patients with the lowest RECINT score (0\u20136) had the lowest probability of cancer recurrence (1- and 5-year recurrence of 16%) in comparison with other groups (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The RECINT model may be useful for stratifying the risk of recurrence in patients with non-muscle-invasive bladder cancer and may allow for identification of those who may benefit the most from adjuvant BCG immunotherapy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00432-020-03202-0","type":"journal-article","created":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T11:02:43Z","timestamp":1585738963000},"page":"2099-2108","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Selected protein expression in a new prognostic model for patients with non-muscle-invasive bladder cancer"],"prefix":"10.1007","volume":"146","author":[{"given":"Aleksandra","family":"Semeniuk-Wojta\u015b","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arkadiusz","family":"Lubas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Szczepan","family":"Cierniak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Urszula","family":"Brz\u00f3skowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomasz","family":"Syry\u0142o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henryk","family":"Zieli\u0144ski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafa\u0142","family":"Stec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,4,1]]},"reference":[{"issue":"2","key":"3202_CR1","first-page":"155","volume":"11","author":"DC Allred","year":"1998","unstructured":"Allred DC, Harvey JM, Berardo M, Clark GM (1998) Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11(2):155\u2013168","journal-title":"Mod Pathol"},{"key":"3202_CR2","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/modpathol.3880300","volume":"14","author":"A Alsheikh","year":"2001","unstructured":"Alsheikh A, Mohamedali Z, Jones E et al (2001) Comparison of the WHO\/ISUP classification and cytokeratin 20 expression in predicting the behavior of low-grade papillary urothelial tumors. Mod Pathol 14:267\u2013272","journal-title":"Mod Pathol"},{"issue":"1","key":"3202_CR3","doi-asserted-by":"publisher","first-page":"e0210635","DOI":"10.1371\/journal.pone.0210635","volume":"14","author":"A Apollo","year":"2019","unstructured":"Apollo A, Ortenzi V, Scatena C et al (2019) Molecular characterization of low grade and high grade bladder cancer. PLoS ONE 14(1):e0210635","journal-title":"PLoS ONE"},{"issue":"1","key":"3202_CR4","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/cdd.2017.169","volume":"25","author":"BJ Aubrey","year":"2018","unstructured":"Aubrey BJ, Kelly GL, Janic A et al (2018) How does p53 induce apoptosis and how does this relate to p53-mediated tumour suppression? Cell Death Differ 25(1):104\u2013113","journal-title":"Cell Death Differ"},{"key":"3202_CR5","unstructured":"Babjuk M, Burger M, Comp\u00e9rat E et al. EAU guidelines on non\u2013muscle-invasive urothelial carcinoma of the bladder cancer (TaT1 and CIS)."},{"key":"3202_CR6","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.eururo.2013.07.021","volume":"65","author":"M Brausi","year":"2014","unstructured":"Brausi M, Oddens J, Sylvester R et al (2014) Side effects of Bacillus Calmette\u2013Guerin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genitourinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG. Eur Urol 65:69\u201376","journal-title":"Eur Urol"},{"issue":"2","key":"3202_CR7","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.eururo.2012.07.033","volume":"63","author":"M Burger","year":"2013","unstructured":"Burger M, Catto JW, Dalbagni G et al (2013) Epidemiology and risk factors of urothelial bladder cancer. Eur Urol 63(2):234\u2013241","journal-title":"Eur Urol"},{"issue":"5","key":"3202_CR8","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.7314\/APJCP.2012.13.5.2229","volume":"13","author":"JX Chen","year":"2012","unstructured":"Chen JX, Deng N, Chen X et al (2012) A novel molecular grading model: combination of Ki67 and VEGF in predicting tumor recurrence and progression in non-invasive urothelial bladder cancer. Asian Pac J Cancer Prev 13(5):2229\u20132234","journal-title":"Asian Pac J Cancer Prev"},{"key":"3202_CR9","doi-asserted-by":"publisher","first-page":"5541","DOI":"10.2147\/OTT.S146990","volume":"10","author":"J Cui","year":"2017","unstructured":"Cui J, Chen S, Bo Q et al (2017) Preoperative prognostic nutritional index and nomogram predicting recurrence-free survival in patients with primary non-muscle-invasive bladder cancer without carcinoma in situ. Onco Targets Ther 10:5541\u20135550","journal-title":"Onco Targets Ther"},{"key":"3202_CR10","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1186\/s12885-016-2361-7","volume":"16","author":"EL de Maturana","year":"2016","unstructured":"de Maturana EL, Picornell A, Masson-Lecomte A et al (2016) Prediction of non-muscle invasive bladder cancer outcomes assessed by innovative multimarker prognostic models. BMC Cancer 16:351","journal-title":"BMC Cancer"},{"issue":"1","key":"3202_CR11","doi-asserted-by":"publisher","first-page":"42.e13","DOI":"10.1016\/j.urolonc.2013.05.004","volume":"32","author":"W Ding","year":"2014","unstructured":"Ding W, Gou Y, Sun C et al (2014) Ki-67 is an independent indicator in non-muscle invasive bladder cancer (NMIBC); combination of EORTC risk scores and Ki-67 expression could improve the risk stratification of NMIBC. Urol Oncol 32(1):42.e13\u201319","journal-title":"Urol Oncol"},{"key":"3202_CR12","unstructured":"Ferlay J, Soerjomataram I, Ervik M et al (2013) GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer"},{"issue":"5","key":"3202_CR13","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1016\/j.juro.2009.07.016","volume":"182","author":"J Fernandez-Gomez","year":"2009","unstructured":"Fernandez-Gomez J, Madero R, Solsona E et al (2009) Predicting non-muscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmetie\u2013Guerin: the CUETO scoring model. J Urol 182(5):2195\u20132203","journal-title":"J Urol"},{"key":"3202_CR14","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ebiom.2016.08.051","volume":"12","author":"T Ieda","year":"2016","unstructured":"Ieda T, Muto S, Shimizu F et al (2016) Development and validation of a novel recurrence risk stratification for initial non-muscle invasive bladder cancer in Asia. EBioMedicine 12:98\u2013104","journal-title":"EBioMedicine"},{"issue":"4","key":"3202_CR15","doi-asserted-by":"publisher","first-page":"389","DOI":"10.4103\/0971-5916.159250","volume":"141","author":"PK Jaiswal","year":"2015","unstructured":"Jaiswal PK, Goel A, Mittal RD (2015) Survivin: a molecular biomarker in cancer. Indian J Med Res 141(4):389\u2013397","journal-title":"Indian J Med Res"},{"issue":"4","key":"3202_CR16","doi-asserted-by":"publisher","first-page":"855","DOI":"10.3349\/ymj.2016.57.4.855","volume":"57","author":"HS Kim","year":"2016","unstructured":"Kim HS, Ku JH, Kim SJ et al (2016) Prognostic Factors for recurrence and progression in Korean non-muscle-invasive bladder cancer patients: a retrospective, multi-institutional study. Yonsei Med J 57(4):855\u2013864","journal-title":"Yonsei Med J"},{"key":"3202_CR17","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/S0022-5347(01)64484-7","volume":"158","author":"K Kurth","year":"1997","unstructured":"Kurth K, Tunn U, Ay R et al (1997) Adjuvant chemotherapy for superficial transitional cell bladder carcinoma: long-term results of a European Organization for Research and Treatment of Cancer randomized trial comparing doxorubicin, ethoglucid and transurethral resection alone. J Urol 158:378\u2013384","journal-title":"J Urol"},{"key":"3202_CR18","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s00345-015-1598-0","volume":"34","author":"RJM Lammers","year":"2016","unstructured":"Lammers RJM, Hendriks JCM, Rodriguez FO et al (2016) Prediction model for recurrence probabilities after intravesical chemotherapy in patients with intermediate-risk non-muscle-invasive bladder cancer, including external validation. World J Urol 34:173\u2013180","journal-title":"World J Urol"},{"key":"3202_CR19","doi-asserted-by":"publisher","first-page":"6029","DOI":"10.1158\/1078-0432.CCR-06-0206","volume":"12","author":"E Lopez-Knowles","year":"2006","unstructured":"Lopez-Knowles E, Hernandez S, Kogevinas M et al (2006) The p53 pathway and outcome among patients with T1G3 bladder tumors. Clin Cancer Res 12:6029\u20136036","journal-title":"Clin Cancer Res"},{"issue":"2","key":"3202_CR20","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","volume":"56","author":"PU Malmstr\u00f6m","year":"2009","unstructured":"Malmstr\u00f6m PU, Sylvester RJ, Crawford DE et al (2009) An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmetie\u2013Gu\u00e9rin for non-muscle-invasive bladder cancer. Eur Urol 56(2):247\u2013256","journal-title":"Eur Urol"},{"key":"3202_CR21","unstructured":"Mostofi FK, Sobin LH, Torloni H (Eds) (1973) Histological typing of urinary bladder tumours. Geneva: World Health Organization"},{"key":"3202_CR22","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/S0022-5347(17)32741-6","volume":"152","author":"RB Nadler","year":"1994","unstructured":"Nadler RB, Catalona WJ, Hudson MA, Ratliff TL (1994) Durability of the tumor-free response for intravesical bacillus Calmette\u2013Guerin therapy. J Urol 152:367\u2013373","journal-title":"J Urol"},{"issue":"5","key":"3202_CR23","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/j.juro.2010.06.147","volume":"184","author":"KG Nepple","year":"2010","unstructured":"Nepple KG, Lightfoot AJ, Rosevear HM et al (2010) Bacillus Calmette\u2013Gu\u00e9rin with or without interferon \u03b1-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of non-muscle invasive bladder cancer. J Urol 184(5):1915\u20131919","journal-title":"J Urol"},{"key":"3202_CR24","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/S0022-5347(17)36198-0","volume":"149","author":"W Oosterlinck","year":"1993","unstructured":"Oosterlinck W, Kurth KH, Schroder F et al (1993) A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J Urol 149:749\u2013752","journal-title":"J Urol"},{"issue":"11","key":"3202_CR25","doi-asserted-by":"publisher","first-page":"485.e7","DOI":"10.1016\/j.urolonc.2016.05.014","volume":"34","author":"N Passoni","year":"2016","unstructured":"Passoni N, Gayed B, Kapur P et al (2016) Cell-cycle markers do not improve discrimination of EORTC and CUETO risk models in predicting recurrence and progression of non-muscle-invasive high-grade bladder cancer. Urol Oncol 34(11):485.e7\u2013485.e14","journal-title":"Urol Oncol"},{"issue":"6","key":"3202_CR26","first-page":"5068","volume":"14","author":"SA Poletajew","year":"2017","unstructured":"Poletajew SA, Majek A, Magusiak P et al (2017) Availability and patterns of intravesical BCG instillations. Urol J 14(6):5068\u20135070","journal-title":"Urol J"},{"key":"3202_CR27","doi-asserted-by":"crossref","unstructured":"Shang PF, Kwong J, Wang ZP et al (2011) Intravesical Bacillus Calmette\u2013Gu\u00e9rin versus epirubicin for Ta and T1 bladder cancer. Cochrane database syst rev 2011(5):CD006885","DOI":"10.1002\/14651858.CD006885.pub2"},{"key":"3202_CR28","doi-asserted-by":"crossref","unstructured":"Sobecki M, Mrouj K, Camasses A et al (2016) The cell proliferation antigen Ki-67 organises heterochromatin. eLife 5:e13722","DOI":"10.7554\/eLife.13722"},{"issue":"3","key":"3202_CR29","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","volume":"49","author":"RJ Sylvester","year":"2006","unstructured":"Sylvester RJ, van der Meijden AP, Oosterlinck W et al (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol Eur Urol 49(3):466\u2013477","journal-title":"Eur Urol Eur Urol"},{"key":"3202_CR30","first-page":"973406","volume":"2014","author":"T Todenh\u00f6fer","year":"2014","unstructured":"Todenh\u00f6fer T, Hennenlotter J, Esser M et al (2014) Stepwise application of urine markers to detect tumor recurrence in patients undergoing surveillance for non-muscle-invasive bladder. Cancer Dis Markers 2014:973406","journal-title":"Cancer Dis Markers"},{"issue":"7492","key":"3202_CR31","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nature12965","volume":"507","author":"Weinstein JN Cancer Genome Atlas Research Network","year":"2014","unstructured":"Weinstein JN Cancer Genome Atlas Research Network (2014) Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507(7492):315\u2013322","journal-title":"Nature"},{"key":"3202_CR32","unstructured":"Wysocka J, Wysocki WM, Jaszczy\u0144ski J (2010) Rak p\u0119cherza moczowego. Klasyfikacja TNM. Available: https:\/\/www.mp.pl\/onkologia\/klasyfikacja-tnm\/64320,rak-pecherza-moczowego-klasyfikacja-tnm"},{"issue":"7","key":"3202_CR33","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1046\/j.1464-410x.2000.00547.x","volume":"85","author":"K Zieger","year":"2000","unstructured":"Zieger K, Wolf H, Olsen PR, Hojgaard K (2000) Long-term follow-up of noninvasive bladder tumours (stage Ta): recurrence and progression. BJU Int 85(7):824\u2013828","journal-title":"BJU Int"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-020-03202-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-020-03202-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-020-03202-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T23:27:03Z","timestamp":1617233223000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-020-03202-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,1]]},"references-count":33,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["3202"],"URL":"https:\/\/doi.org\/10.1007\/s00432-020-03202-0","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,1]]},"assertion":[{"value":"10 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None declared.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}